Aeglea Bio Therapeutics, Inc. AGLE
We take great care to ensure that the data presented and summarized in this overview for Aeglea BioTherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGLE
View allLatest Institutional Activity in AGLE
Top Purchases
Top Sells
About AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Insider Transactions at AGLE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 06
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Indirect |
6,700
-19.67%
|
$241,200
$36.76 P/Share
|
|
Oct 25
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Indirect |
300
-0.87%
|
$10,800
$36.43 P/Share
|
|
Sep 03
2024
|
Scott L Burrows Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,531
-13.73%
|
$518,868
$28.17 P/Share
|
|
Apr 25
2024
|
Fairmount Funds Management LLC |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,639,680
+47.53%
|
-
|
|
Feb 15
2024
|
Cameron Turtle Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+0.05%
|
$3,600
$9.82 P/Share
|
|
Dec 29
2023
|
Fairmount Funds Management LLC |
BUY
Other acquisition or disposition
|
Indirect |
812,076
+50.0%
|
-
|
|
Dec 29
2023
|
Fairmount Funds Management LLC |
SELL
Other acquisition or disposition
|
Indirect |
3,435,480
-100.0%
|
-
|
|
Dec 22
2023
|
Scott L Burrows Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,953
+50.0%
|
-
|
|
Nov 24
2023
|
Fairmount Funds Management LLC |
BUY
Conversion of derivative security
|
Indirect |
3,435,480
+50.0%
|
-
|
|
Nov 24
2023
|
Cameron Turtle Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
723,440
+49.22%
|
-
|
|
Aug 25
2022
|
Marcio Souza Director |
BUY
Open market or private purchase
|
Direct |
90,000
+50.0%
|
$0
$0.56 P/Share
|
|
Jun 08
2022
|
Jr. Michael Conick Hanley Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
28,200
+43.79%
|
$0
$0.71 P/Share
|
|
Mar 16
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
80,079
+12.7%
|
$160,158
$2.34 P/Share
|
|
Mar 15
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
42,417
+8.22%
|
$42,417
$1.86 P/Share
|
|
Mar 14
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
67,472
+13.53%
|
$67,472
$1.93 P/Share
|
|
Mar 11
2022
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
75,000
+31.2%
|
$150,000
$2.08 P/Share
|
|
Mar 11
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
34,777
+8.73%
|
$69,554
$2.06 P/Share
|
|
Dec 13
2021
|
Armen Shanafelt Director |
BUY
Open market or private purchase
|
Direct |
14,685
+8.92%
|
$44,055
$3.65 P/Share
|
|
Dec 10
2021
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
10,526
+3.1%
|
$31,578
$3.75 P/Share
|
|
Dec 10
2021
|
Armen Shanafelt Director |
BUY
Open market or private purchase
|
Direct |
13,516
+9.08%
|
$40,548
$3.65 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 812K shares |
|---|---|
| Exercise of conversion of derivative security | 3.64M shares |
| Grant, award, or other acquisition | 135K shares |
| Open market or private sale | 25.5K shares |
|---|---|
| Other acquisition or disposition | 3.44M shares |